Author: Alligator Bioscience

Posted Date:

April 10, 2026

Alligator Bioscience Provides an Update on Mitazalimab

Alligator Bioscience

April 10, 2026
Notice of Annual General Meeting in Alligator Bioscience AB

Alligator Bioscience

March 30, 2026
The Nomination Committee’s Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)

Alligator Bioscience

March 27, 2026
Alligator Bioscience Publishes Annual Report for 2025

Alligator Bioscience

March 26, 2026
New data from Investigator‑Initiated Study Evaluating Alligator Bioscience’s Mitazalimab to be Presented at AACR Annual Meeting 2026

Alligator Bioscience

March 18, 2026
Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform

Alligator Bioscience

March 10, 2026
Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22

Alligator Bioscience

March 2, 2026
Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB

Alligator Bioscience

February 27, 2026
Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update

Alligator Bioscience

February 12, 2026
Invitation to Alligator Bioscience’s Earnings Call on 12 February 2026

Alligator Bioscience

February 8, 2026